Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected stage II or III melanoma
100 Clinical Results associated with Immuno-Designed Molecules SA
0 Patents (Medical) associated with Immuno-Designed Molecules SA
100 Deals associated with Immuno-Designed Molecules SA
100 Translational Medicine associated with Immuno-Designed Molecules SA